Assessment of pomegranate whitening cream on melasma

Phase 2

Recruiting

• Conditions: Melasma.; Chloasma; L81.1

• Registration Number: IRCT20161207031288N6
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 November 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Mild to moderate melasma with minimum grade of Melasma area and severity index = 1
Age range 18-50
Signing consent form, voluntarily and knowingly

Exclusion Criteria

Pregnancy or lactation
Using oral corticosteroids or isotretinoin within 28 days prior to the study
Any active skin disease at test area including rosacea, eczema, atrophy, acne
Using any light sensitizing medicine within 3 months prior to the study
Use of topical lightening products like alpha hydroxy acid, beta hydroxy acid, and retinoid component within 21 days prior to the study
Documented allergy to components of the cream
History of laser treatment or dermabrasion or deep facial peeling within the past 3 months prior to the study
Using contraceptive or hormonal medicines

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Modified melasma severity index. Timepoint: Before intervention, 4 weeks later, 8 weeks after intervention. Method of measurement: Modified Melasma Area and Severity Index.

Secondary Outcome Measures

Name	Time	Method
Skin pH. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Cutometer MPA 580.;Skin sebum. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Cutometer MPA 580.;Skin melanin and erythem. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Cutometer MPA 580.;Transepidermal watre loss. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Cutometer MPA 580.;Size and value of skin spot. Timepoint: At the beginning (before start of the intervention) and 4 and 8 weeks after start of the intervention. Method of measurement: Visio face device.